

## Information for Colorado Prescribers of Prescription Drugs

### OXBRYTA® (voxelotor) tablets (for oral use, for oral suspension)

The prices listed below are Wholesale Acquisition Costs ("WAC") established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about the WAC of this drug is being provided to Colorado prescribers pursuant to Colorado law, to give prescribers information about the WAC price of marketed drugs as well as generic drugs in the same therapeutic class.

<b>Marketed Product*:</b>	<b>WAC Package</b>	<b>Package size</b>
OXBRYTA 500 MG TABLET	\$11,042.02	90
OXBRYTA 300 MG TABLET	\$11,042.02	60
OXBRYTA 300 MG TABLET	\$11,042.02	90
OXBRYTA 300 MG TABLET FOR SUSP	\$11,042.02	60
OXBRYTA 300 MG TABLET FOR SUSP	\$11,042.02	90

#### **Generics\*\*:**

N/A

\*Prices shown are for the lowest dosage of the product.

This information is being provided pursuant to Colorado HB 19-1131. The information is accurate as of March 06, 2023. The prices listed are WAC prices, which represent Pfizer's published list prices for the products sold to wholesalers, before any discount, rebate, or other price reduction. The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product's WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed.

\*\*This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made. For additional drug and price information, including a listing of generic products, see: <http://www.pfizer.com/coprescribers>

Data as of: 06-Mar-2023